39 reports

  • Oncology Drugs Market Characteristics

Hormone therapy does not work for all types of cancer, but doctors use this therapy for patients with hormone sensitive or hormone dependent cancers such as breast cancer, prostate cancer, ovarian cancer, uterine or endometrial cancer and kidney cancer. Hormone therapy

  • Oncology
  • Pharmaceutical
  • World
  • Gilead Sciences, Inc.
  • Novartis AG
  • Global - Endometrial Cancer Hormone Therapy Market (Billion US$), 2016 & 2023
  • Figure 7-3: Global - Endometrial Cancer Hormone Therapy Market (Billion US$), 2016 & 2023
  • Cancer
  • Endometrial Cancer
  • Pathology
  • Therapy
  • World
  • CNS

Hormone therapy is being used now-a-days to treat cancer especially to treat prostate and breast cancers. Hormone therapy

  • Pharmaceutical
  • R&D
  • World
  • Market Size
  • Teva Pharmaceutical Industries Ltd.
  • 5.1 Global Prostate Cancer Hormonal Therapy Market & Forecast
  • 1. Global Prostate Cancer - Hormonal Therapy Drugs Market
  • Prostate Cancer
  • Therapy
  • World
  • Market Size
  • PROVENGE group
  • Global prostate cancer hormonal therapy drugs 303
  • TABLE 124 Global prostate cancer hormonal therapy drugs 303
  • Cancer
  • Pathology
  • Prostate Cancer
  • World
  • Market Size
  • Key Prostate Cancer Hormone Therapy Drugs & Companies: 2016
  • Cancer
  • Pathology
  • Prostate Cancer
  • Therapy
  • World
  • REFERENCE CODE GDHC139PIDR | PUBLICATION DATE DECEMBER 2016

Breast Cancer Hormone Therapy Side Effects.

  • Breast Cancer
  • Cancer
  • Epidemiology
  • Targeted Therapy
  • Therapy
  • Leading Hormone Cancer Treatments by 2015 Estimated Sales
  • Hormone Therapy: At a Glance
  • Cancer
  • Targeted Therapy
  • Therapy
  • Novartis AG
  • Pfizer Inc.
  • Clinical Trial profile. 88 Trial Title
  • Clinical Trial Profile Snapshots
  • Clinical Trial
  • Drug Discovery And Development
  • Monoclonal Antibody
  • Prostate Cancer
  • Therapy
  • 5. All the trials included are unique trials.

John' s Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer GDCT## NCT##, MSKCC-##; NCI-G##-##; ##-## Central Nervous System Fatigue, Leukemias, Lymphoma, Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Plasma Cell Neop

  • Clinical Trial
  • Hormone
  • Hospital
  • Neurology
  • Therapy
  • Clinical Trial Profile Snapshots

CANCER HORMONE THERAPY WITH ARZOXIFENE HYDROCHLORIDE IN TREATING WOMEN WITH METASTATIC REFRACTORY OVARIAN CANCER OR PRIMARY PERITONEAL CANCER GDCT## NCT##, CDR##; LILLY-H##Z-MC-JWWJ; MDA-DM-##; ##; CDR## ONCOLOGY EPITHELIAL OVARIAN CANCER, METASTATIC OVARIAN CANCER, PE

  • Cancer
  • Hospital
  • Ovarian Cancer
  • Pathology
  • Therapy
  • Clinical Trial profile. 264 Trial Title
  • Clinical Trial profile. 449 Trial Title
  • Cancer
  • Chemotherapy
  • Endometrial Cancer
  • Hospital
  • Therapy
  • Key Prostate Cancer Hormone Therapy Drugs & Companies: 2016
  • Cancer
  • Pathology
  • Prostate Cancer
  • Therapy
  • United States
  • 06.5 MANAGEMENT

ASCO Treatment Guidelines: HER-## Positive Breast Cancer Hormonal Therapy Hormonal therapy is currently not preferred for the treatment of HER-## positive breast cancer patients.

  • Breast Cancer
  • Therapy
  • Celgene Corporation
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Docetaxel

Usually when treatments like cryotherapy or prostate surgery fail the next step is either another type of treatment or prostate cancer hormone therapy.

  • Hormone
  • Prostate Cancer
  • China
  • AstraZeneca Pharmaceutical Co., Ltd
  • Bristol-Myers Squibb Company
  • Clinical Trial profile. 932 Trial Title
  • Chronic Disease
  • Endocrine Disease
  • Hormone
  • Musculoskeletal Disorder
  • Therapy
  • PRODUCT PROFILE - TRELSTAR
  • PRESENTS A PRODUCT PROFILE OF TRELSTAR.

Competitive Assessment THE PROSTATE CANCER HORMONE THERAPY MARKET IS CROWDED WITH LHRH AGONISTS.

  • Cancer
  • Epidemiology
  • Prostate Cancer
  • Therapy
  • Astellas Pharma Inc.
  • KEY LATE-STAGE CLINICAL TRIALS OF BUPARLISIB
  • REFERENCE CODE GDHC92PIDR | PUBLICATION DATE JANUARY 2015
  • Breast Cancer
  • Cancer
  • Epidemiology
  • Targeted Therapy
  • Therapy
  • Docetaxel
  • Hormone
  • Pharmaceutical
  • Prostate Cancer
  • China
  • AstraZeneca Pharmaceutical Co., Ltd
  • CLINICAL TRIAL PROFILE. 706 TRIAL TITLE
  • Clinical Trial Profile Snapshots
  • Clinical Trial
  • Drug Discovery And Development
  • Hospital
  • Ovarian Cancer
  • Therapy
  • Clinical Trial profile. 105 Trial Title
  • Clinical Trial Profile Snapshots
  • Cancer
  • Hospital
  • Monoclonal Antibody
  • Neurology
  • Therapy
  • Clinical Trial profile. 518 Trial Title
  • Clinical Trial profile. 848 Trial Title
  • Cancer
  • Cervical Cancer
  • Chemotherapy
  • Endometrial Cancer
  • Therapy
  • Clinical Trial Profile Snapshots

Cancer Hormone Therapy with Arzoxifene Hydrochloride in Treating Women with Metastatic Refractory Ovarian Cancer or Primary Peritoneal Cancer GDCT## NCT##, CDR##; LILLY-H##Z-MC-JWWJ; MDA-DM-##; ##; CDR## Oncology Epithelial Ovarian Cancer, Metastatic Ovarian Cancer, Pe

  • Cancer
  • Clinical Trial
  • Drug Discovery And Development
  • Ovarian Cancer
  • Therapy
  • Clinical Trial profile. 2279 Trial Title
  • Clinical Trial profile. 533 Trial Title
  • Chemotherapy
  • Clinical Trial
  • Drug Discovery And Development
  • Pharmaceutical
  • Therapy
  • Official Title
  • Clinical Trial Profile Snapshots
  • Clinical Trial
  • Drug Discovery And Development
  • Monoclonal Antibody
  • Pharmaceutical
  • Therapy
  • KEY LATE-STAGE CLINICAL TRIALS OF BUPARLISIB
  • REFERENCE CODE GDHC353CFR | PUBLICATION DATE JANUARY 2015
  • Breast Cancer
  • Clinical Trial
  • Targeted Therapy
  • Therapy
  • Europe
  • Ovarian Cancer Hormone Therapy Market: Drivers and Restraints, 2015-2025
  • Global Ovarian Cancer Hormone Therapy Market: Revenue Forecast ($bn), 2015-2025
  • Therapy
  • World
  • Market Size
  • 9.2 References

Hormone therapy for cancer.

  • Cancer Immunotherapy
  • Monoclonal Antibody
  • Oncology
  • Therapy
  • World
  • KEY LATE-STAGE CLINICAL TRIALS OF BUPARLISIB
  • REFERENCE CODE GDHC352CFR | PUBLICATION DATE JANUARY 2015
  • Breast Cancer
  • Clinical Trial
  • Targeted Therapy
  • Therapy
  • Novartis AG
  • KEY LATE-STAGE CLINICAL TRIALS OF BUPARLISIB
  • REFERENCE CODE GDHC355CFR | PUBLICATION DATE JANUARY 2015
  • Breast Cancer
  • Clinical Trial
  • Targeted Therapy
  • Therapy
  • Novartis AG